Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 29, 16 January 2024
Open
Access | Article
Maternal embryonic leucine zipper kinase in cancer progress and therapeutic potentials
* Author to whom correspondence should be addressed.
Abstract
This review delves into the investigation of Maternal Embryonic Leucine Zipper Kinase (MELK) and its significance in different cancer types. The primary emphasis is placed on understanding its role in cancer cell proliferation, migration, invasion, and resistance to therapeutic interventions. The intricate mechanisms of action exhibited by MELK are of significant importance in the context of cancer progression. These mechanisms encompass a wide range of biological processes, including gene regulation, cellular activities, and interactions at the tissue level. This highlights the multifaceted nature of MELK’s involvement in cancer development and underscores its significance in this context. This essay explores the potential of MELK as a diagnostic and prognostic biomarker, with a focus on its altered expression patterns in various cancer types. Furthermore, this study delves into the investigation of MELK as a highly promising target for cancer therapy. It provides an in-depth analysis of the progress made in the development of MELK inhibitors and explores their potential clinical applications. The research endeavours in this study focus on addressing challenges related to therapeutic resistance and biomarker validation. Additionally, the investigation explores potential opportunities for combination therapies and personalised medicine approaches. The future directions of research on maternal embryonic leucine zipper kinase (MELK) encompass an in-depth investigation into its underlying molecular mechanisms, the validation of clinical biomarkers associated with MELK, and the exploration of effective combination strategies involving MELK. The role of MELK in cancer and the possibility to utilize it as a target for therapy have garnered significant attention due to their potential to advance precision cancer care and improve patient outcomes.
Keywords
MELK, Cancer progression, Combination Therapy, Precision Medicine.
References
1. R. Ganguly, A. Mohyeldin, J. Thiel, H.I. Kornblum, M. Beullens, I. Nakano, MELK—a conserved kinase: functions, signaling, cancer, and controversy, Clinical and translational medicine 4 (2015) 1-8.
2. P. Mondal, B. Kaur, J. Natesh, S.M. Meeran, The emerging role of miRNA in the perturbation of tumor immune microenvironment in chemoresistance: Therapeutic implications, Seminars in cell & developmental biology, Elsevier, 2022, pp. 99-113.
3. H. Sun, H. Ma, H. Zhang, M. Ji, Up-regulation of MELK by E2F1 promotes the proliferation in cervical cancer cells, International Journal of Biological Sciences 17(14) (2021) 3875.
4. Q. Zhang, C. Zhong, J. Shen, S. Chen, Y. Jia, S. Duan, Emerging role of LINC00461 in cancer, Biomedicine & Pharmacotherapy 152 (2022) 113239.
5. L. Beke, C. Kig, J.T. Linders, S. Boens, A. Boeckx, E. van Heerde, M. Parade, A. De Bondt, I. Van den Wyngaert, T. Bashir, MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells, Bioscience reports 35(6) (2015) e00267.
6. S. Chen, Q. Zhou, Z. Guo, Y. Wang, L. Wang, X. Liu, M. Lu, L. Ju, Y. Xiao, X. Wang, Inhibition of MELK produces potential anti‐tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway, Journal of Cellular and Molecular Medicine 24(2) (2020) 1804-1821.
7. R. Edupuganti, J.M. Taliaferro, Q. Wang, X. Xie, E.J. Cho, F. Vidhu, P. Ren, E.V. Anslyn, C. Bartholomeusz, K.N. Dalby, Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth, Bioorganic & medicinal chemistry 25(9) (2017) 2609-2616.
8. S. Crispi, R.A. Calogero, M. Santini, P. Mellone, B. Vincenzi, G. Citro, G. Vicidomini, S. Fasano, R. Meccariello, G. Cobellis, Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target, PLoS One 4(9) (2009) e7016.
9. Z. Zhang, C. Sun, C. Li, X. Jiao, B.B. Griffin, S. Dongol, H. Wu, C. Zhang, W. Cao, R. Dong, Upregulated MELK leads to doxorubicin chemoresistance and M2 macrophage polarization via the miR-34a/JAK2/STAT3 pathway in uterine leiomyosarcoma, Frontiers in oncology 10 (2020) 453.
10. R.B. Craveiro, M. Ehrhardt, M.I. Holst, T. Pietsch, D. Dilloo, In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy, Oncotarget 5(16) (2014) 7149.
11. M.K. Pitner, J.M. Taliaferro, K.N. Dalby, C. Bartholomeusz, MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies, Expert Opinion on Therapeutic Targets 21(9) (2017) 849-859.
12. Y. Zhao, T. Du, L. Du, P. Li, J. Li, W. Duan, Y. Wang, C. Wang, Long noncoding RNA LINC02418 regulates MELK expression by acting as a ceRNA and may serve as a diagnostic marker for colorectal cancer, Cell death & disease 10(8) (2019) 568.
13. R. Kuner, M. Fälth, N.C. Pressinotti, J.C. Brase, S.B. Puig, J. Metzger, S. Gade, G. Schäfer, G. Bartsch, E. Steiner, The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer, Journal of molecular medicine 91 (2013) 237-248.
14. F. Hu, C. Gong, Y. Gai, D. Jiang, Q. Liu, S. Wang, M. Hu, R. Pi, H. Shu, J. Hu, [18F] F-ET-OTSSP167 Targets Maternal Embryo Leucine Zipper Kinase for PET Imaging of Triple-Negative Breast Cancer, Molecular Pharmaceutics 18(9) (2021) 3544-3552.
15. C. Gu, Y.K. Banasavadi-Siddegowda, K. Joshi, Y. Nakamura, H. Kurt, S. Gupta, I. Nakano, Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner, Stem cells 31(5) (2013) 870-881.
16. M. Kanda, Y. Kodera, Molecular mechanisms of peritoneal dissemination in gastric cancer, World journal of gastroenterology 22(30) (2016) 6829.
17. C. Speers, S.G. Zhao, V. Kothari, A. Santola, M. Liu, K. Wilder-Romans, J. Evans, N. Batra, H. Bartelink, D.F. Hayes, Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer, Clinical Cancer Research 22(23) (2016) 5864-5875.
18. B. Li, J. Yan, T. Phyu, S. Fan, T.-H. Chung, N. Mustafa, B. Lin, L. Wang, P.J.A. Eichhorn, B.-C. Goh, MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma, Blood, The Journal of the American Society of Hematology 134(23) (2019) 2046-2058.
19. R.S. Kohler, H. Kettelhack, A.M. Knipprath-Mészaros, A. Fedier, A. Schoetzau, F. Jacob, V. Heinzelmann-Schwarz, MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells, Gynecologic oncology 145(1) (2017) 159-166.
20. X. Zhang, J. Wang, Y. Wang, G. Liu, H. Li, J. Yu, R. Wu, J. Liang, R. Yu, X. Liu, MELK inhibition effectively suppresses growth of glioblastoma and cancer stem-like cells by blocking AKT and FOXM1 pathways, Frontiers in Oncology 10 (2021) 608082.
21. R.B. Mokhtari, T.S. Homayouni, N. Baluch, E. Morgatskaya, S. Kumar, B. Das, H. Yeger, Combination therapy in combating cancer, Oncotarget 8(23) (2017) 38022.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-279-4
- ISBN (Online)
- 978-1-83558-280-0
- Published Date
- 16 January 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/29/20240631
- Copyright
- 16 January 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited